Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10622227rdf:typepubmed:Citationlld:pubmed
pubmed-article:10622227lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:10622227lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10622227lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:10622227lifeskim:mentionsumls-concept:C0599851lld:lifeskim
pubmed-article:10622227lifeskim:mentionsumls-concept:C0521457lld:lifeskim
pubmed-article:10622227lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:10622227pubmed:issue23lld:pubmed
pubmed-article:10622227pubmed:dateCreated2000-1-18lld:pubmed
pubmed-article:10622227pubmed:abstractTextSince 1988, patients with Parkinson's disease have participated in clinical trials evaluating the efficacy of transplantation of human fetal dopamine cells into the caudate and putamen. Transplantation of fetal tissue leads to clinical benefits in some patients which is associated with a reduction of the amount of LDOPA administered. Major issues in transplant research need to be addressed before this technique can be widely applied. In this review, a pool of 35 patients was generated from the published cases of human fetal tissue transplantation. This group of transplant recipients was examined for motor improvement and reduction in L-DOPA dosage at one year post-transplant. Issues addressed in this review include the benefits of unilateral vs bilateral transplantation, age of the transplant recipient, solid vs suspensions of fetal mesencephalon and the number of fetal donors per recipient.lld:pubmed
pubmed-article:10622227pubmed:languageenglld:pubmed
pubmed-article:10622227pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10622227pubmed:citationSubsetIMlld:pubmed
pubmed-article:10622227pubmed:statusMEDLINElld:pubmed
pubmed-article:10622227pubmed:monthOctlld:pubmed
pubmed-article:10622227pubmed:issn0024-3205lld:pubmed
pubmed-article:10622227pubmed:authorpubmed-author:FreedC RCRlld:pubmed
pubmed-article:10622227pubmed:authorpubmed-author:ClarksonE DEDlld:pubmed
pubmed-article:10622227pubmed:issnTypePrintlld:pubmed
pubmed-article:10622227pubmed:day29lld:pubmed
pubmed-article:10622227pubmed:volume65lld:pubmed
pubmed-article:10622227pubmed:ownerNLMlld:pubmed
pubmed-article:10622227pubmed:authorsCompleteYlld:pubmed
pubmed-article:10622227pubmed:pagination2427-37lld:pubmed
pubmed-article:10622227pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:meshHeadingpubmed-meshheading:10622227...lld:pubmed
pubmed-article:10622227pubmed:year1999lld:pubmed
pubmed-article:10622227pubmed:articleTitleDevelopment of fetal neural transplantation as a treatment for Parkinson's disease.lld:pubmed
pubmed-article:10622227pubmed:affiliationDepartment of Medicine and Pharmacology, University of Colorado School of Medicine, Denver 80262, USA.lld:pubmed
pubmed-article:10622227pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10622227pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10622227lld:pubmed